225 related articles for article (PubMed ID: 34262257)
1. Evaluation of Ceftazidime/Avibactam Administration in
Dai Y; Chang W; Zhou X; Yu W; Huang C; Chen Y; Ma X; Lu H; Ji R; Ying C; Wang P; Liu Z; Yuan Q; Xiao Y
Drug Des Devel Ther; 2021; 15():2899-2905. PubMed ID: 34262257
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the
Viala B; Zaidi FZ; Bastide M; Dumont Y; Le Moing V; Jean-Pierre H; Godreuil S
Microb Drug Resist; 2019 Nov; 25(9):1325-1329. PubMed ID: 31225764
[No Abstract] [Full Text] [Related]
3. Pharmacokinetic and Pharmacodynamic Analysis of Ceftazidime/Avibactam in Critically Ill Patients.
Stein GE; Smith CL; Scharmen A; Kidd JM; Cooper C; Kuti J; Mitra S; Nicolau DP; Havlichek DH
Surg Infect (Larchmt); 2019 Jan; 20(1):55-61. PubMed ID: 30351195
[TBL] [Abstract][Full Text] [Related]
4. The Potential Use of Ceftazidime-Avibactam Against Carbapenem Resistant
Nasomsong W; Nulsopapon P; Changpradub D; Pongchaidecha M; Pungcharoenkijkul S; Juntanawiwat P; Simsiriporn W; Santimaleeworagun W
Drug Des Devel Ther; 2021; 15():3095-3104. PubMed ID: 34295150
[TBL] [Abstract][Full Text] [Related]
5. Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates.
Montero MM; Domene Ochoa S; López-Causapé C; Luque S; Sorlí L; Campillo N; López Montesinos I; Padilla E; Prim N; Angulo-Brunet A; Grau S; Oliver A; Horcajada JP
Microbiol Spectr; 2021 Sep; 9(1):e0058521. PubMed ID: 34319141
[TBL] [Abstract][Full Text] [Related]
6. Optimal treatment of ceftazidime-avibactam and aztreonam-avibactam against bloodstream infections or lower respiratory tract infections caused by extensively drug-resistant or pan drug-resistant (XDR/PDR)
Kang Y; Xie L; Yang J; Cui J
Front Cell Infect Microbiol; 2023; 13():1023948. PubMed ID: 37457958
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Determine Optimal Dosing of Ceftazidime-Avibactam for the Treatment of Acute Pulmonary Exacerbations in Patients with Cystic Fibrosis.
Bensman TJ; Wang J; Jayne J; Fukushima L; Rao AP; D'Argenio DZ; Beringer PM
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784670
[TBL] [Abstract][Full Text] [Related]
8. Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme.
Stone GG; Newell P; Gasink LB; Broadhurst H; Wardman A; Yates K; Chen Z; Song J; Chow JW
J Antimicrob Chemother; 2018 Sep; 73(9):2519-2523. PubMed ID: 29912399
[TBL] [Abstract][Full Text] [Related]
9. Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals.
Ludwig E; Konkoly-Thege M; Kuti JL; Nicolau DP
Int J Antimicrob Agents; 2006 Nov; 28(5):433-8. PubMed ID: 17046212
[TBL] [Abstract][Full Text] [Related]
10.
Karlowsky JA; Kazmierczak KM; Bouchillon SK; de Jonge BLM; Stone GG; Sahm DF
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670424
[TBL] [Abstract][Full Text] [Related]
11. Use of Monte Carlo simulation to optimize antibiotic selection for bloodstream infections caused by Enterobacteriaceae in Shandong Province, China.
Wang C; Bai Y; Li R; Shen C; Zhang J
Diagn Microbiol Infect Dis; 2020 Jun; 97(2):115039. PubMed ID: 32253072
[TBL] [Abstract][Full Text] [Related]
12. In vivo efficacy of humanized exposures of Ceftazidime-Avibactam in comparison with Ceftazidime against contemporary Enterobacteriaceae isolates.
MacVane SH; Crandon JL; Nichols WW; Nicolau DP
Antimicrob Agents Chemother; 2014 Nov; 58(11):6913-9. PubMed ID: 25223999
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic/pharmacodynamic modelling to evaluate the efficacy of various dosing regimens of ceftazidime/avibactam in patients with pneumonia caused by Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae: a multicentre study in northern China.
Kang Y; Zhou Q; Cui J
J Glob Antimicrob Resist; 2021 Dec; 27():67-71. PubMed ID: 34428596
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial Activities of Ceftazidime-Avibactam and Comparator Agents against Clinical Bacteria Isolated from Patients with Cancer.
Hachem R; Reitzel R; Rolston K; Chaftari AM; Raad I
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28115350
[TBL] [Abstract][Full Text] [Related]
15. Ceftazidime-Avibactam Antimicrobial Activity and Spectrum When Tested Against Gram-negative Organisms From Pediatric Patients: Results From the INFORM Surveillance Program (United States, 2011-2015).
Sader HS; Huband MD; Duncan LR; Flamm RK
Pediatr Infect Dis J; 2018 Jun; 37(6):549-554. PubMed ID: 29206750
[TBL] [Abstract][Full Text] [Related]
16. Bactericidal activity, absence of serum effect, and time-kill kinetics of ceftazidime-avibactam against β-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
Keepers TR; Gomez M; Celeri C; Nichols WW; Krause KM
Antimicrob Agents Chemother; 2014 Sep; 58(9):5297-305. PubMed ID: 24957838
[TBL] [Abstract][Full Text] [Related]
17. Synergistic Activity of Imipenem in Combination with Ceftazidime/Avibactam or Avibactam against Non-MBL-Producing Extensively Drug-Resistant Pseudomonas aeruginosa.
Zhang Y; Zhao J; Han J; Fan Y; Xiong Z; Zou X; Li B; Liu X; Li Z; Lu B; Cao B
Microbiol Spectr; 2022 Apr; 10(2):e0274021. PubMed ID: 35315696
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of ceftazidime-avibactam and comparators against Enterobacterales and Pseudomonas aeruginosa isolates from Central Europe and Israel, 2014-2017 and 2018.
Kristóf K; Adámková V; Adler A; Gospodarek-Komkowska E; Rafila A; Billová S; Możejko-Pastewka B; Kiss F
Diagn Microbiol Infect Dis; 2021 Sep; 101(1):115420. PubMed ID: 34091111
[TBL] [Abstract][Full Text] [Related]
19. Clinical experience with ceftazidime/avibactam for treatment of antibiotic-resistant organisms other than Klebsiella pneumoniae.
Santevecchi BA; Smith TT; MacVane SH
Int J Antimicrob Agents; 2018 Apr; 51(4):629-635. PubMed ID: 29408227
[TBL] [Abstract][Full Text] [Related]
20. Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa.
Nichols WW; Stone GG; Newell P; Broadhurst H; Wardman A; MacPherson M; Yates K; Riccobene T; Critchley IA; Das S
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30061279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
